Heart Failure – Geographic Focus: China – Heart failure | China In-Depth | China
Heart failure presents a major public health burden in China. With a rapidly rising urban population and a growing trend of unhealthy lifestyle, heart failure is expected to affect a sizeable population of the country. The treatment of acute heart failure (AHF) is dominated by older, cost-effective generic drugs; however, we expect the growing uptake of recently approved SGLT-2 inhibitors—canagliflozin (Janssen’s Invokana), dapagliflozin (AstraZeneca’s Farxiga), and empagliflozin (Eli Lilly’s Jardiance)—will lead the heart failure market to grow significantly during the forecast period. Nonetheless, a significant unmet need will continue to exist for patients with chronic heart failure with preserved ejection fraction (HF-pEF)—where treatment options are limited—representing an opportunity for drug developers in this space. In addition, the ongoing reforms in the regulatory and A&R landscape of China are expected to encourage MNCs to enter the heart failure market.
QUESTION ANSWERED
PRODUCT DESCRIPTION
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
Geography
China
Primary research
Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 50 cardiologists
Epidemiology
Diagnosed prevalence of chronic heart failure and diagnosed incidence of acute heart failure in urban versus rural China; clinically relevant and market-relevant drug-treatable populations
FORECAST
10-year, annualized, drug-level sales and patient share of key heart failure therapies through 2031, based on primary and secondary market research to formulate bottom-up assumptions
EMERGING THERAPIES
Phase III/PR: 10 drugs; Phase II: 3 drugs; coverage of select preclinical and Phase I products
Table of contents
- Heart Failure - Geographic Focus: China - Heart failure | China In-Depth | China
- China In-Depth_Heart Failure_2022
- Chronic Heart Failure - China In-Depth - Market Forecast Assumptions
- Acute Heart Failure - China In-Depth - Market Forecast Assumptions
- Executive Summary Deck_China In-Depth - 2022
- Acute Heart Failure - China In-Depth - Market Forecast Dashboard
- Chronic Heart Failure - China In-Depth - Market Forecast Dashboard
Samantha Wang, Healthcare Research & Data Analyst, China In-Depth. With an educational background in business management, Ms. Wang has experience researching the regulatory reforms in China pertaining to drug and medical device registration and market access. She is now involved in drafting disease landscape reports focusing on the treatment of various indications in China, such as gastroesophageal cancer, Alzheimer’s disease, rheumatoid arthritis, and heart failure. She also provides the team with local language and cultural support, as well as participates in interviewing physicians in China and answering client queries.
Sunali D. Goonesekera, S.M., Senior Manager, Epidemiology. Prior to joining Clarivate, Ms. Goonesekera conducted epidemiological research on racial/ethnic disparities in metabolic diseases at the New England Research Institute and lead-authored two manuscripts. She has contributed to multiple publications in peer-reviewed journals in epidemiology and the biological sciences. She holds a master’s degree in epidemiology from the Harvard School of Public Health and a B.A. in biology (Honors) from Dartmouth College.